Keytruda® (pembrolizumab) – Expanded indication
July 6, 2021 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.
Download PDF
